Journal article
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
Abstract
INTRODUCTION: We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. Preliminary efficacy data suggested activity in patients with recurrent small cell lung cancer (SCLC). Based on these data, we performed a phase II study of obatoclax mesylate plus topotecan in patients with relapsed SCLC to assess efficacy.
Authors
Paik PK; Rudin CM; Pietanza MC; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R
Journal
Lung Cancer, Vol. 74, No. 3, pp. 481–485
Publisher
Elsevier
Publication Date
December 2011
DOI
10.1016/j.lungcan.2011.05.005
ISSN
0169-5002